NASDAQ : KALV
KalVista Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 27 USD (At close: Jun 10, 2026) · Market cap 1.44B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.44B |
| Enterprise Value | 1.44B |
Dates
| Measure | Value |
|---|
| Earnings Date | Jul 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 53.24M |
| Shares Outstanding | 53.24M |
| Shares Change (YoY) | +9.26% |
| Shares Change (QoQ) | -1.09% |
| Owned by Insiders (%) | 1.77% |
| Owned by Institutions (%) | 107.54% |
| Float | 38.18M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.56 |
| Forward PS | 7.96 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 12.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.17 |
| Quick Ratio | 4.97 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.37 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -52.22% |
| Weighted Average Cost of Capital (WACC) | 4.06% |
| Revenue Per Employee | $416,291 |
| Profits Per Employee | -$494,316 |
| Employee Count | 275 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -5.80M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.11 |
| 52-Week Price Change | +82.93% |
| 50-Day Moving Average | 24.01 |
| 200-Day Moving Average | 16.84 |
| Relative Strength Index (RSI) | 75.89 |
| Average Volume (20 Days) | 3,209,124 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.84M |
| Short Previous Month | 12.05M |
| Short % of Shares Out | 12.85% |
| Short % of Float | 17.92% |
| Short Ratio (days to cover) | 0.94 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 114.48M |
| Gross Profit | 58.47M |
| Operating Income | -140.00M |
| Pretax Income | -141.73M |
| Net Income | -135.94M |
| EBITDA | -138.45M |
| EBIT | -140.00M |
| Loss Per Share | -$2.51 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 285.03M |
| Total Debt | 284.31M |
| Net Cash | 718,000 |
| Net Cash Per Share | $0.01 |
| Equity (Book Value) | -19.65M |
| Book Value Per Share | -0.38 |
| Working Capital | 253.39M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -89.32M |
| Capital Expenditures | -2.39M |
| Depreciation & Amortization | 1.56M |
| Net Borrowing | 208.57M |
| Free Cash Flow | -91.71M |
| FCF Per Share | -$1.72 |
Margins
| Measure | Value |
|---|
| Gross Margin | 51.07% |
| Operating Margin | -122.30% |
| Pretax Margin | -123.81% |
| Profit Margin | -118.74% |
| EBITDA Margin | -120.94% |
| EBIT Margin | -122.30% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -9.26% |
| Shareholder Yield | -9.26% |
| Earnings Yield | -9.46% |
| FCF Yield | -6.38% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $28.60 |
| Price Target Difference | 5.93% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 80.76% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -2.28 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |